Clinical Trials

Pancreatic Neoplasms

NCT07424664 2026-02-20

A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer

30 enrolled

Phase 3 Active not recruiting

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT05502237 2026-01-30

STAR-121

1,021 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

182 enrolled

Solid Tumor

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

33 enrolled

Bile Duct Neoplasms, Cholangiocarcinoma

NCT07337447 2026-01-13

REWENEC 01

Phase EARLY_PHASE1 Active not recruiting

122 enrolled

Endocrine

Carcinoma, Neuroendocrine

NCT04656535 2026-01-07

AB154 Combined With AB122 for Recurrent Glioblastoma

46 enrolled

CNS

Glioblastoma, Recurrence

NCT05007782 2025-12-29

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Phase 1 Recruiting

416 enrolled

Advanced Solid Tumor

NCT07283848 2025-12-26

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Phase 2 Withdrawn

Phase 2 Active not recruiting

Stomach Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Phase 1/2 Recruiting

31 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04791839 2025-11-05

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04660812 2025-10-20

ARC-9

Phase 1/2 Completed

227 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT05886634 2025-10-20

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

16 enrolled

Sarcoma

Liposarcoma, Sarcoma

NCT06790706 2025-10-06

IMMUNORARE5

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

154 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT06082960 2025-09-10

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Phase 1 Active not recruiting

45 enrolled

Solid Tumors

NCT04772989 2025-08-28

ARC-12

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

94 enrolled

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT05024097 2025-08-27

PANTHER

43 enrolled

Phase 2 Active not recruiting

Rectal Neoplasms

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase 1/2 Completed

173 enrolled

Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05632848 2025-07-21

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Phase 2 Completed

47 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05724563 2025-05-21

Domvanalimab and Zimberelimab in Advanced Liver Cancers

58 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

NCT05915442 2025-05-20

SBRT-AMICO

23 enrolled

Genitourinary

Oligometastatic Prostate Cancer

NCT06532565 2025-05-16

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Phase 1 Recruiting

154 enrolled

Advanced Solid Tumors

NCT05177770 2025-05-08

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Terminated

16 enrolled 10 charts

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT05130177 2025-05-07

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

26 enrolled

Dermatologic

Melanoma

NCT06431633 2025-04-10

ARIAN

Phase 3 Recruiting

129 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT03628677 2025-02-04

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

75 enrolled

Solid Tumor, Unspecified, Adult

NCT03846310 2024-12-09

ARC-4

77 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04087018 2024-09-19

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

18 enrolled

Advanced Solid Tumors

NCT04747470 2024-09-03

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Phase 1 Terminated

13 enrolled 18 charts

Advanced Solid Tumors

NCT06155396 2024-02-28

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

116 enrolled

Uterine Cervical Neoplasms

NCT06166589 2023-12-12

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

19 enrolled

Pancreatic Neoplasms

NCT04892875 2023-11-30

PANTHEoN

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Pharyngeal Neoplasms

NCT06128460 2023-11-30

Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.

24 enrolled

Uterine Cervical Neoplasms

NCT06107114 2023-11-22

CZCNRHNSCC

Phase 2 Unknown

52 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06055738 2023-09-28

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

20 enrolled

Locally Advanced Cervical Cancer

NCT06009029 2023-08-24

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

96 enrolled